AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$GH

Chudova Darya sold $1.4M of GH

Chudova Darya (Chief Technology Officer) sold 7,738 shares of Guardant Health, Inc. (GH) at $178.00 ($1.38M total) on 2026-09-15.

Original reporting
SEC EDGAR · Chudova Darya
Published Sep 17, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GH
Bearish
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBearishLow
01

Why it matters

The sale reduces insider ownership, which can be interpreted as a slight bearish signal.

02

Market read

First-report insider sale provides new data for traders assessing short-term sentiment.

03

What to watch

Potential upcoming stock dilution or financing activities could be a factor.

Relevance 6/10Novelty 7/10Timing: filed Sep 17 after market close

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$GHBearishMedium confidence
Context

Chief Technology Officer sold 7,738 shares for $1.38M, reducing her stake to 70,635 shares.

Expected impact

Potential modest dip in near-term price.

Evidence & confidence

Sale size is notable for a C-level exec, but not large enough to suggest major concerns.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company outlook.

Key entities

  • Company
    Guardant Health, Inc.

    US-listed biotech firm (ticker GH).

  • Person
    Chudova Darya

    Chief Technology Officer of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

OCT 20
$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

insidermonkey.com3 min
OCT 9
$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.

onclive.com6 min